Press Сentre
Наши новости
The “ChemRar Center for Development of Innovative and Import-substituting Drugs” project was approved in 2009 by the Presidential Commission for Modernisation and Technological Development of Russia’s Economy. It included the following activities:
Designing a technological platform for finished dosage forms development and trial production of ...
06.03.2018
Russian innovative infrastructure, science and business leaders gathered at the third Congress of NeuroNet Industrial Union, which was held on February 3rd, 2018 at ASI’s Boiling point. The main goal of the event was to define the further development vector for NeuroNet market to help Russian companies win leading positions in global labor ...
08.02.2018
The winners of the sixth annual National Rating of Russian High-Tech Rapidly Developing Companies TechUspekh-2017, organized by RVC together with PwC, the Association of Innovative Regions of Russia and the National Research University Higher School of Economics, were announced on December 12, 2017. Data for more than one hundred domestic ...
21.12.2017
The Award Ceremony for the domestic pharmaceutical and medical industry institutional awards of the Ministry of Industry and Trade of the Russian Federation was held at the opening ceremony of the Russian Health Care Week 2017 on December 4, 2017. Irina Tyrnova, who has headed Viriom since its founding in 2009, and under whose supervision ELPIDA® ...
08.12.2017
In early November, IPHARMA, a company of ChemRar Group, received two approvals from the Ministry of Healthcare of the Russian Federation to conduct phase I clinical trials of Ventvil® and Slavinorm®.
Protocol No. HEP-VTL-01 “A double-blind, randomized, placebo-controlled trial of the safety and tolerability of increasing doses of Ventvil® in ...
17.11.2017
On November 14–16, the 21st Russian Oncology Congress was held in Moscow. It is the largest international event in the field of oncology, which is attended by over 5,000 doctors annually.
The permanent organizers of the Congress: N.N. Blokhin Russian Cancer Research Center and the Russian Society of Clinical Oncology under the aegis of the ...
16.11.2017
October 30, 20017. IPHARMA, a company of ChemRar Group, was authorized by the Ministry of Healthcare of the Russian Federation to conduct phase I trial of Hondrolux®.
Protocol No. OA-CLX-01 “A double-blind, randomized, placebo-controlled trial of the safety and tolerability of increasing doses of Hondrolux® in single and subsequent repeated ...
31.10.2017
On November 8 at 11 a.m., IPHARMA, a company of ChemRar Group, will conduct a webinar on the topic “Opportunities for application of adaptive design in clinical trials”.
Adaptive design is an innovative approach that allows to conduct a clinical trial more efficiently (with fewer patients in a shorter time) or to increase the probability of ...
30.10.2017
Technopark SKOLKOVO held a panel discussion on the topics “Civilization is (not) at risk in an age of artificial intelligence” and “Neurointerface technology without borders” as part of the Open Innovation 2017 Forum on October 17, 2017, where Andrey Ivaschenko, the Chairman of the Board of Directors of ChemRar High-Tech Center and the leader of ...
19.10.2017
The Scientific Symposium “The First in the 21st Century. Innovations in Russian HIV treatment”, dedicated to the Russian innovative drug for a first line treatment of HIV — ELPIDA®, was held in St. Petersburg as part of the Second Forum on HIV Treatment on October 5, 2017. The Symposium was held on the opening day of the Forum, chaired by ...
13.10.2017
On October 5, 2017 in St. Petersburg as part of the Second Forum on HIV, the Viriom company of ChemRar Group conducts a scientific symposium “Innovations in HIV treatment in Russia”, dedicated to the first Russian innovative drug in the 21st century for first-line HIV treatment — ELPIDA® (elsulfavirin).
The Viriom symposium will be held on the ...
03.10.2017
On September 14–15, 2017 ChemRar Group presented their innovative developments at the Biotechmed-2017 conference in Gelendzhik, and already registered innovative and import-substituting drugs, whose full production cycle, including the active substance, took place in Russia. The main topics of discussion at the conference this year were a ...
22.09.2017
Публикации в печатных и электронных СМИ
Видео
Фото
